[go: up one dir, main page]

FR2959416B1 - Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament - Google Patents

Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament

Info

Publication number
FR2959416B1
FR2959416B1 FR1053426A FR1053426A FR2959416B1 FR 2959416 B1 FR2959416 B1 FR 2959416B1 FR 1053426 A FR1053426 A FR 1053426A FR 1053426 A FR1053426 A FR 1053426A FR 2959416 B1 FR2959416 B1 FR 2959416B1
Authority
FR
France
Prior art keywords
antibodies
preparation
medicinal product
medicinal
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1053426A
Other languages
English (en)
Other versions
FR2959416A1 (fr
Inventor
Laurence Boumsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
MONOCLONAL ANTIBODIES THERAPEUTICS MAT-BIOPHARMA
MONOCLONAL ANTIBODIES THERAPEUTICS MAT BIOPHARMA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONOCLONAL ANTIBODIES THERAPEUTICS MAT-BIOPHARMA, MONOCLONAL ANTIBODIES THERAPEUTICS MAT BIOPHARMA filed Critical MONOCLONAL ANTIBODIES THERAPEUTICS MAT-BIOPHARMA
Priority to FR1053426A priority Critical patent/FR2959416B1/fr
Priority to PCT/FR2011/051005 priority patent/WO2011138557A2/fr
Priority to US13/696,097 priority patent/US20130216476A1/en
Priority to EP11723558A priority patent/EP2566511A2/fr
Publication of FR2959416A1 publication Critical patent/FR2959416A1/fr
Application granted granted Critical
Publication of FR2959416B1 publication Critical patent/FR2959416B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR1053426A 2010-05-03 2010-05-03 Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament Expired - Fee Related FR2959416B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1053426A FR2959416B1 (fr) 2010-05-03 2010-05-03 Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
PCT/FR2011/051005 WO2011138557A2 (fr) 2010-05-03 2011-05-03 Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
US13/696,097 US20130216476A1 (en) 2010-05-03 2011-05-03 Use of an anti-cd71 antibody for preparing a medicament
EP11723558A EP2566511A2 (fr) 2010-05-03 2011-05-03 Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1053426A FR2959416B1 (fr) 2010-05-03 2010-05-03 Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament

Publications (2)

Publication Number Publication Date
FR2959416A1 FR2959416A1 (fr) 2011-11-04
FR2959416B1 true FR2959416B1 (fr) 2012-06-22

Family

ID=42671926

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1053426A Expired - Fee Related FR2959416B1 (fr) 2010-05-03 2010-05-03 Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament

Country Status (4)

Country Link
US (1) US20130216476A1 (fr)
EP (1) EP2566511A2 (fr)
FR (1) FR2959416B1 (fr)
WO (1) WO2011138557A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
LT3292149T (lt) 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
EP3325006A4 (fr) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York Procédés de traitement du cancer exprimant cd166
EP3156417A1 (fr) * 2015-10-13 2017-04-19 Affimed GmbH Anticorps fv multivalents
TWI752012B (zh) 2016-03-04 2022-01-11 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
CN110662766A (zh) 2017-03-09 2020-01-07 赛托姆克斯治疗学股份有限公司 Cd147抗体、可激活cd147抗体及其制备和使用方法
EP3762420A1 (fr) 2018-03-09 2021-01-13 CytomX Therapeutics, Inc. Anticorps activables de cd147 et procédés de fabrication et d'utilisation associés
WO2021061867A1 (fr) 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anticorps anti-cd47, anticorps anti-cd47 activables, et leurs méthodes d'utilisation
WO2021163033A1 (fr) * 2020-02-10 2021-08-19 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de détection de cellules subissant une ferroptose à l'aide d'un anticorps
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
JP2024534880A (ja) 2021-09-01 2024-09-26 バイオジェン・エムエイ・インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用
WO2025024334A1 (fr) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Conjugués de ciblage de cellules hématopoïétiques et procédés associés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029597A1 (en) * 2004-03-31 2006-02-09 Chimeric Technologies IgA antibody protein as a cytotoxic drug
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells

Also Published As

Publication number Publication date
US20130216476A1 (en) 2013-08-22
WO2011138557A2 (fr) 2011-11-10
FR2959416A1 (fr) 2011-11-04
EP2566511A2 (fr) 2013-03-13
WO2011138557A3 (fr) 2011-12-29

Similar Documents

Publication Publication Date Title
FR2959416B1 (fr) Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
EP2869784A4 (fr) Appareil oral pour l'administration d'un médicament
IT1403011B1 (it) "cartuccia per la preparazione di un prodotto liquido"
EP2623100A4 (fr) Préparation pour améliorer la solubilité d'un médicament médiocrement soluble
EP2720743A4 (fr) Masque pour l'administration de médicament inhalé
EP2792372A4 (fr) Adhésif médical biodégradable et procédé de préparation et d'utilisation associé
IL239530A0 (en) Oral gel comprising zinc-amino acid complex
EP2533834A4 (fr) Dispositif d'administration d'un médicament
EP2547332A4 (fr) Dispositifs implantables hétérogènes pour la délivrance de médicaments
EP2540311A4 (fr) Corps composite pour libération d'antigènes ou de médicaments
EP2895526A4 (fr) Polyamines ramifiées pour l'administration de matières biologiquement
IT1403780B1 (it) Dispositivo per l'infusione di farmaci.
EP2658970A4 (fr) Humanisation express d'anticorps
EP2548543A4 (fr) Dispositif d'assistance pour jambe
IT1403162B1 (it) "cartuccia per la preparazione di un prodotto liquido"
EP2702976A4 (fr) Récipient pour l'administration d'un médicament
FR2959107B1 (fr) Unite d'application d'un produit cosmetique
EP2648697A4 (fr) Procédés de formation de miniémulsions et utilisation associée pour l'administration d'agents bioactifs
FR2956313B1 (fr) Appareil pour l'administration d'une substance visqueuse pendant une operation chirurgicale.
FR2945952B1 (fr) Anticorps anti-ck8 pour utilisation comme medicament.
FR2995536B1 (fr) Unite medicale pour l'injection de rubidium 82 a un patient
EP3318269C0 (fr) Utilisation du polypeptide angiopoietin-like 4 (angptl4) dans la fabrication d'un médicament pour le traitementde de la proeinurie
FR2960418B1 (fr) Ensemble glenoidien pour prothese d'epaule
FR2998801B1 (fr) Ensemble a usage medical pour l'administration d'un produit a un patient
FR2989086B1 (fr) Composes thiol et leur utilisation pour la synthese d'oligonucleotides modifies

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: LFB BIOTECHNOLOGIES, FR

Effective date: 20130107

TP Transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130820

ST Notification of lapse

Effective date: 20150130